InDevR Expands Commercial Portfolio for Coronavirus Vaccine Characterization
BOULDER, Colo., Dec. 10, 2020 — InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its VaxArray® Spike Protein Kit and SARS-CoV-2 Spike Protein Standard for vaccine antigen quantification.
Of the many coronavirus vaccine candidates in development, several are based on either whole virus or recombinant spike-protein. Quantification of the spike protein concentration, or “potency,” at various steps in the manufacturing process is critical for characterizing vaccine performance. Many developers rely on in-house immunoassays for early protein quantification work. To streamline vaccine development, InDevR offers an off-the-shelf VaxArray kit for multiplexed quantification of spike protein based on binding to both mAb CR3022 and ACE2 and a spike protein calibration standard that can be paired with the VaxArray kit or other immunoassays. These new kits complement the already available VaxArray Coronavirus SeroAssay kit, giving vaccine developers a single platform for both clinical efficacy and vaccine potency testing.
“An essential reagent for product quantification by any immunoassay is the calibration standard. Most vaccine developers will create an internal calibration standard that matches the quality characteristics of their product. However, this approach does not allow for comparison of protein content or potency between vaccines. The well-characterized and stabilized full-length spike protein we now offer will serve well as calibration standard in our VaxArray assays as well other spike-protein immunoassays,” said InDevR’s CEO, Dr. Kathy Rowlen. For more information, please visit: indevr.com/vaxarray-for-coronavirus.
About InDevR—Based in Boulder, CO, InDevR is a biotechnology company poised to significantly impact vaccine process optimization and manufacturing with powerful new protein characterization tools. Venture-backed by Adjuvant Capital and funded by NIH and Bill & Melinda Gates Foundation, InDevR has launched several successful life science tool product lines to enable vaccine development and serological research. InDevR provides testing and custom services for companies that need support in the vaccine development space. The VaxArray products have already improved influenza vaccine bioprocess optimization in novel influenza vaccine manufacturing platforms, and now are also supporting SARAS-CoV-2 vaccination development. The company plans to aggressively build on that success by expanding into new applications—many of which have the potential to meaningfully reduce the complexity, execution timeline, and cost of essential public health vaccines and biotherapeutics.